Advances in the Study of the Ubiquitin-Editing Enzyme A20

Wenya Bai, Siying Huo, Junjie Li and Jianlin Shao*

Department of Anesthesiology, First Affiliated Hospital of Kunming Medical University, Kunming, China

Ubiquitin modification is a common post-translational protein modification and an important mechanism whereby the body regulates protein levels and functions. As a common enzyme associated with ubiquitin modification, the ubiquitin-editing enzyme A20 may be closely associated with the development of numerous pathological processes through its different structural domains. The aim of this paper is to provide an overview of the following: advances in ubiquitination research, the structure and function of A20, and the relationships between A20 and immune inflammatory response, apoptosis, necroptosis, pyroptosis, and autophagy.

Keywords: ubiquitination, ubiquitin-editing enzyme A20, inflammatory response, apoptosis, necroptosis, pyroptosis, autophagy

INTRODUCTION

A20 was first reported in 1990, the stimulation of tumor necrosis factor alpha (TNFa) can lead to the upregulation of A20 expression in human umbilical vein endothelial cells; hence, the A20 is also known as TNFa-induced protein 3 (TNFAIP3) (Opipari et al., 1990). Furthermore, A20 has the functions of both deubiquitinase and ubiquitin ligase, so it is called ubiquitin editing enzyme (Wertz et al., 2004). Several studies have confirmed that A20 is a potent anti-inflammatory protein that mediates inflammation in mammals, which is attributed to its ability to suppress Nuclear Factor-kappa B (NF-κB) signaling in a negative feedback manner (Harhaj and Dixit, 2012). However, recently more and more studies have shown that A20 can also play another function that is independently of NF-κB regulation, such as protect cells from death (Priem et al., 2020). Here we review the role of A20 in regulating the following five essential functions: 1) The immune inflammation response, 2) The apoptosis, 3) The necroptosis, 4) The pyroptosis, 5) The Cell autophagy. We further provide insight into potential mechanisms by which A20 functions in the context of a multi-protein ubiquitin-editing complex.

Advances in Ubiquitination Research

A ubiquitin molecule is a protein polypeptide consisting of 76 amino acid molecules. Ubiquitination is a common post-translational protein modification (Goldstein et al., 1975). In the presence of three successive enzymes (E1 ubiquitin-activating enzyme, E2 ubiquitin-conjugating enzyme, and E3 ligase) and ATP, the ubiquitin molecule is covalently attached to a lysine residue of the substrate protein through its terminal carboxyl group, then making the formation of monomeric or polymultication (Komander, 2009; Komander and Rape, 2012); ubiquitination modifies the substrate protein. First, E1 utilizes ATP and activates ubiquitin. Then, through its cysteine residue, E1 forms a high-energy thioester bond with the C-terminus of the ubiquitin molecule. This is followed by the transfer of the ubiquitin molecule from E1 to the cysteine residue of E2 to form a thioester intermediate. Finally, E3 selectively recognizes the corresponding E2, ubiquitin, and substrate protein, and catalyzes the formation of an isopeptide bond between

*Correspondence: Jianlin Shao cmushaoj@aliyun.com

Specialty section: This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology

Received: 29 December 2021
Accepted: 28 February 2022
Published: 03 May 2022

Citation: Bai W, Huo S, Li J and Shao J (2022) Advances in the Study of the Ubiquitin-Editing Enzyme A20. Front. Pharmacol. 13:845262. doi: 10.3389/fphar.2022.845262

REVIEW

published: 03 May 2022
doi: 10.3389/fphar.2022.845262
ubiquitin and a certain lysine residue on the substrate protein. Notably, there are seven lysine residues on the ubiquitin molecule, all of which can attach to the C-terminus of another ubiquitin molecule, resulting in seven polyubiquitin chains with different linkages (K6, K11, K27, K29, K33, K48, K63). Alternatively, the N-terminal end of the ubiquitin molecule can be linked to the C-terminal end of another ubiquitin molecule by a peptide bond to form a linear ubiquitin chain (which is also called M1-Linked ubiquitin chain), resulting in the polyubiquitination of the substrate protein (Cohen and Strickson, 2017; Haakonsen and Rape, 2019). Different ubiquitination modifications can exert different physiological effects. For example, K48-Linked polyubiquitination modification can make the substrate protein susceptible to recognition and subsequent proteasomal degradation. Studies show that A20-mediated K48-Linked polyubiquitination modification of receptor-interacting kinase 3 (RIPK3) may be related to the switching between mycobacterium tuberculosis-induced apoptosis and necrosis (Fu et al., 2021). In addition, A20 can enhance the K48-Linked polyubiquitination modification of Tumor necrosis factor receptor-associated factor 6 (TRAF6) to suppress autophagy under hypoxic conditions, then inhibiting osteoclastogenesis in human periodontal ligament cells (Yan et al., 2020). A20 can mediate K48-Linked polyubiquitination modification of RNF138 for proteasomal degradation to affect NF-κB activation and lymphomagenesis (Yu et al., 2021); K63-Linked and M1-Linked polyubiquitination modification is involved in serving as a scaffolding network for the formation of signaling complexes. Studies indicated that A20 can downregulate the K63-Linked polyubiquitination modification of TRAF6, which is involved in the anti-neuroinflammatory effects of bavachin (Wang H et al., 2021); In addition, A20 can also play an anti-microbial host defense role through affecting the K63-Linked polyubiquitination modification of different substrate proteins (Liu L. et al., 2020; Liu et al., 2021); Polyubiquitination at K6 is correlated with the development of nonalcoholic steatohepatitis; K29-Linked polyubiquitination is associated with the innate cellular immunity of macrophages (Wang et al., 2020; Gao et al., 2021; Tracz and Bialek, 2021).

The process of polyubiquitination modification is a reversible process; the substrate protein can also undergo deubiquitination by deubiquitinating enzymes (DUBs). Currently, more than 100 DUBs have been identified, which are classified into the following six families based on their structural domains: ubiquitin C-terminal hydrolyases, ubiquitin-specific proteases, ovarian tumor domain proteases (OTUs), Josephins, JAB1/MPN/MOV34 (JAMMs) and MCP1IP. Of these, the ubiquitin-editing enzyme A20 is by far the most studied DUB of the OTU family. The common feature of DUBs is that they contain specific protein recognition structural domains, such as the zinc finger ubiquitin-specific protease domain (ZnF-UBP), the ubiquitin-interacting motif (UIM) and the ubiquitin-binding structural domain (UBA), which is closely involved in the function of DUBs.

The Structure and Function of A20

A20 is a member of the OTU family and has a molecular weight of 90 kDa, Subsequent studies have identified two NF-κB binding sites in the promoter of A20, which demonstrating that A20 can be transcriptionally upregulated by Nuclear Factor-kappa B (NF-κB) in response to stimuli (e.g., TNF, IL-1, ROS, virus), providing negative feedback control of NF-κB signaling pathway (Pujari et al., 2013). A20 has an OTU structural domain at the N-terminal end, which can hydrolyze the K63-Linked polyubiquitin chains, to initially regulate signal transduction. Moreover, the C-terminus has seven tandem zinc finger structural domains (ZnF4 and ZnF7 domains are common). The ZnF4 structural domain has an E3 ubiquitin ligase function and can catalyze the formation of K48-Linked polyubiquitin chains, to promote degradation of key signaling molecules; the ZnF7 structural domain, however, readily binds to M1-Linked ubiquitin chains; besides, A20 can also disrupts the interactions between E2 and E3, thus attenuates the activation of specific E3 ligases, then disrupts the ubiquitination cascade (Shembade and Harhaj, 2010; Martens et al., 2020). Owing to its deubiquitinating and ubiquitin ligase activities, A20 is called ubiquitin-editing enzyme A20, which can regulate different different pathological processes in a catalytic and non-catalytic manner.

A20 and the Immune Inflammatory Response

When an organism receives a harmful external stimulus, such as infection or tissue and organ damage, an inflammatory response occurs. The inflammatory response converts the external stimulus into biological responses through multiple signaling pathways. The NF-κB signaling pathway is one of the main signaling pathways involved in the molecular transduction of inflammatory signals. When stimulated by external signals, such as IL-1β, TNF-α as well as lipopolysaccharide (LPS), IkBα will be degraded and phosphorylated under the stimulation of upstream signaling molecules TGFβ3-activated kinase (TAK1) and inhibitor of κB kinase (IKK) complexes, allowing NF-κB to enter into the nucleus and activate target genes (Hinz et al., 2012). Under normal physiological conditions, A20 is not expressed (or expressed at very low levels) in most cell types, but when NF-κB is activated, NF-κB can transcriptionally activates the expression of A20 via the two NF-κB sites in the A20 promoter (Krikos et al., 1992). Several studies have shown that A20 is closely associated with the pathological processes involved in inflammatory and autoimmune diseases, including inflammatory bowel disease (Zhou et al., 2021), rheumatoid arthritis (Malynn and Ma, 2019), chronic inflammatory lung disease (Momtazi et al., 2019), multiple atherosclerotic disease (Perga et al., 2021), lupus nephritis (Sun et al., 2019), and atherosclerosis (Angolano et al., 2021), which is mostly related to that A20 can inhibit the NF-κB signaling pathway in a feedback manner. A20 may inhibit the NF-κB signaling pathway through many mechanisms: 1) During the inflammatory response mediated by IL-1R/Toll-like receptor (TLR4), A20 may inhibit the NF-κB signaling pathway through the two mechanisms: 1) A20 expression is induced and directly target the E3 ligase TRAF6 by disassembling the K63-Linked polyubiquitin chains of TRAF6 via its OTU domain; 2) A20 disrupt the interactions between TRAF6 and its E2 enzymes Ubc13 and UbcH5 cooperating with
the ubiquitin-binding adaptor molecule TAX1BP1 in the first step, then at later times A20 conjugate K48-Linked polyubiquitin chains on Ubc13 and/or UbcH5c via its ZnF4 domain to trigger their proteasomal degradation (Martens and van Loo, 2020). During a TNF-mediated inflammatory response, A20 may hydrolyze the K63-Linked polyubiquitin chain of receptor-interacting kinase 1 (RIPK1) through its OTU structural domain or cause K48-Linked polyubiquitination through the ZnF4 structural domain, thus inhibiting the NF-κB signaling pathway (Shembade and Harhaj, 2012); In addition, A20 can also disrupt the association between E3 ligase complex cellular inhibitor of apoptosis protein 1/2 (cIAP1/2), TRAF2/5 and E2 ubiquitin-conjugating enzyme Ubc13 followed by triggering the ubiquitination and proteasomal degradation of Ubc13 at later time points (Shembade et al., 2010). A20 can also regulate the activation of NF-κB signaling pathway induced by T cell receptor (TCR) and nucleotide oligomerization domain 2 (NOD2) by affecting the ubiquitination level of MALT1 and RIP2, respectively (Hitotsumatsu et al., 2008; Duwel et al., 2009). Furthermore, in the feedback regulation, the ubiquitin modifying functions of A20 can be further enlarged depended on IKBα-mediated phosphorylation of A20 at Ser381 (Hutti et al., 2007). Taken together, it can be concluded that A20 may inhibit NF-κB signaling pathway through distinct mechanisms in a catalytic manner. Chen et al. found that the downregulation of A20 expression can, through the activation of the NF-κB and mitogen-activated protein kinase (MAPK) signaling pathways, exacerbate the inflammatory response induced by medium-wave ultraviolet radiation (Chen et al., 2020). Studies also found that A20 deficient mice is characterized by the infiltration of CD8+ T cells into the CNS, which results in abnormal microglia activation and altered neuronal activity (Mohebiany et al., 2020). In addition, formononetin upregulates A20 via G-protein-coupled receptors, which attenuates atopic dermatitis (Yuan et al., 2021). Furthermore, the LINCO1140/miR-23A20 signaling axis alleviates low density lipoprotein (LDL)-induced inflammatory responses in macrophages (He et al., 2020).

Although A20 is thought to inhibit NF-κB signaling pathway by affecting the ubiquitination levels of multiple target proteins, the physiological role of A20 in regulation of NF-κB was still incompletely clarified. Studies showed that different from A20+/− mice, mice bearing a point mutation in either the OTU domain (A20OTU/OTU mice) or ZnF4 domain (A20ZnF4/ZnF4) do not develop severe inflammatory phenotype (Lu et al., 2013; Wertz et al., 2015), however, the A20ZnF7/ZnF7 mice can spontaneously develop arthritis and other autoimmune diseases. These findings indicate that ZnF7 of A20 may play a more prominent role in regulation of NF-κB (Martens et al., 2020; Razani et al., 2020). The mechanism may be related to that A20 can bind to the M1-Linked polyubiquitin chains of RIPK1 and/or NF-κB essential modulator (NEMO) through its ZnF7 structural domain, to stabilize the M1-Linked ubiquitin chain and protect them from deubiquitinase-mediated cleavage, thus affecting the activation of the IKK complex in a non-catalytic manner (Sun, 2020). However, studies have indicated that the inflammatory phenotype of A20+/− mice (Lee et al., 2000), and mice carrying mutations both in ZnF7 and ZnF4 causes more serious inflammation and NOD-like receptor p3 (NLRP3) inflammasome activation than that of A20ZnF7/ZnF7 mice (Razani et al., 2020), furthermore, Martens and his colleagues have demonstrated that A20 can also bind to the K63-Linked ubiquitin chains of RIPK1 through the ZnF4 domain (Martens et al., 2020), suggesting that ZnF4 and ZnF7 may interact with each other in regulating NF-κB signaling pathway. ZnF4 is largely required for repressing severe inflammatory responses and may play a crucial role in repressing inflammatory response in the absence of a functional ZF7 (Sun, 2020), but both the precise mechanism and whether the E3 ligase activity of ZnF4 is involved in this process need to be further elucidated. Additional studies are urgently needed to further test and determine the functions of ZnF4 and ZnF7 in different physiological status, as well as the role of A20 deubiquitinase catalytic activity, in order to provide a theoretical basis for the treatment of A20-associated autoimmune and inflammatory diseases in the future (Figure 1).

A20 and Apoptosis
A20 Inhibits Apoptosis

Apoptosis is a nonlytic form of regulated programmed cell death (PCD), depending on the activation of the death receptor (DRs) extrinsic or mitochondrial intrinsic pathway (Taylor et al., 2008). In response to stimulation by external pro-apoptotic signals, like TNF, TNF-related apoptosis-inducing ligand (TRAIL), Fas, and death receptor 3/4/5 (DR3/4/5), the initiating caspase protein (Caspase-2/8/9/10/11/12) binds to Fas-associated protein with death domain and RIPs, activating the downstream effector caspase proteins (Caspase-3/6/7) and consequently, apoptosis. Studies have found that the upregulation of A20 expression can inhibit apoptosis induced by microglial exosomes (Chen et al., 2019). A20 interacts with RIPK1 through its ZnF7 structural domain to affect caspase-8 protein expression in intestinal epithelial cells, thereby inhibiting their apoptosis (Liu X. et al., 2020). Furthermore, A20 upregulation inhibits intestinal epithelial cell apoptosis in Crohn’s disease (Zhou et al., 2019) by affecting the functions of tumor necrosis factor receptor 1 (TNFR1), TNFR1-associated death domain protein (TRADD) and RIPK1. In a mouse model with hepatic damage, A20 inhibited the apoptosis of hepatocytes and immune inflammation through the NF-κB signaling pathway, playing a role in the chronic rejection of allogeneic liver transplantation (Li et al., 2019; Jia et al., 2021). Although it is fully recognized that A20 is a key regulator that can prevent cells from apoptosis, the mechanism by which it does are still not completely elucidated. To date, the function of A20 in the TNF signaling have been most extensively studied. Upon binding of TNF to TNFR, A20 was shown to be recruited to the membrane-bound complex I, which is consist of RIPK1, TRADD, TRAF2/5, cIAP1/2, etc, and bound to the M1-Linked polyubiquitin chains of RIPK1 via its ZnF7 domain within minutes, thereby protecting the M1-Linked ubiquitin chains from cylindromatosis (CYLD)-mediated cleavage and repressing the complex I transitioning to a death-inducing cytosolic complex II (Ila: FADD/Caspase-8/TRADD; Iib: FADD/Caspase-8/RIPK1) (Wilson et al., 2009; Draber et al.,
Recently, another study showed that in M1-Linked polyubiquitin chains proficient cells, the ZnF7 domain may play a dominant role in A20’s prosurvival function, but in absence of M1-Linked polyubiquitin chains, the ZnF4 and ZnF7 domains of A20 cooperate to bind to other types of ubiquitin chains associated to Complex I, potentially K63-Linked chains, then protecting cells from apoptosis by deploying its DUB activity (Priem et al., 2019). Except in the TNF signaling, A20 has been also reported to prevent cells from apoptosis in TRAIL signaling. The studies showed that A20 can promote the formation of the K63-Linked polyubiquitin chains on RIPK1 through its ZnF4 domain, then RIPK1 being recruited to death-inducing signaling complex (DISC), and inhibit the dimerization, cleavage of caspase 8, finally suppress TRAIL-induced apoptosis (Bellail et al., 2012; Guo et al., 2018). In addition, A20 can hydrolyse the cullin3-mediated K63-Linked ubiquitination of caspase-8 on the C-terminal region through its OTU domain, then inhibiting caspase-8 activation (Jin et al., 2009; Lim et al., 2017) (Figure 2). Thus, in summary, A20 appears to have the ability to regulate apoptosis in either a catalytic and/or non-catalytic manner, targeting the function of A20 might therefore be of putative therapeutic value in many diseases.

**A20 Promotes Apoptosis**

Paradoxically, some studies also found that A20 can promote apoptosis in some cell types. Kool et al. reported that A20-
deficient Dendritic cells were resistant to apoptosis, caused by upregulation of antiapoptotic proteins Bcl-2 and Bcl-x, which can be transcriptional regulated by NF-κB (Kool et al., 2011). A similar phenomenon was found in A20-deficient B cells and Nasopharyngeal Carcinoma cells (Tavares et al., 2010; Zheng et al., 2017; Fan et al., 2021). Another study suggested that elevated A20 can stabilize the ripoptosome and potentiate its apoptosis-inducing activity, thereby, promote the RIPK1-dependent apoptosis in intestinal epithelial cells (Garcia-Carbonell et al., 2018). Wang et al. also reported that Dot1L transcriptionally activates A20, contributing to RIPK1-dependent apoptosis after cerebral ischemia-reperfusion (Wang J et al., 2021). Recently, a new mechanism related to A20 promoting apoptosis was put forward. The study showed that A20 can repress the expression of its target gene cIAP1/2 through the canonical NF-κB signaling. The changes in cIAP1/2 protein levels promote NIK stabilization and subsequent activation of noncanonical NF-κB signaling. The activated noncanonical NF-κB signaling can further enhance the NIK stabilization in an autocrine manner. Finally, stabilized NIK promotes the formation of the ripoptosome and the execution of cell death (Feoktistova et al., 2020).

Taken together, we assume that A20 play the paradoxically role in apoptosis may be relevant to the different cell types. In addition, the speed at which the target genes respond to the stimulation is worth being paid more attention. But more research will be needed in the future to confirm this hypothesis.

**A20 and Necroptosis**

Necroptosis is a lytic, caspase-independent and calpain dependent form of PCD that can induce inflammatory response. Necroptosis is characterized by the formation of necrosome. Necroptosis shares upstream signaling elements
with apoptosis, but the outcomes of apoptosis and necroptosis were significantly distinct (Linkermann and Green, 2014). Necroptosis can be triggered by DRs, which promote the recruitment of RIPK3 and mixed lineage kinase domain-like protein (MLKL) to RIPK1 forming RIPK1-RIPK3-MLKL signaling complex, which is also called necrosome. Subsequently, RIPK3 can phosphorylate MLKL, and phosphorylated MLKL translocate to the plasma membrane to assemble a pore-forming complex, promoting the release of danger-associated molecular patterns (DAMPs) into the environment, thereby inducing necrptosis (Jin et al., 2009). Of note, necroptosis appears to have evolved as a backup suicide mechanism, when caspase-8 is inhibited (Kaiser et al., 2011; Zhang et al., 2011). Studies show that melatonin can inhibit RIPK3-mediated microglial necroptosis by up-regulating the A20 expression after ICH (Lu et al., 2019). Studies also demonstrated that A20 was indispensable for regulating and controlling necroptosis after traumatic brain injury. They also found that A20 - silencing lead to aggressive necroptosis and attenuate the anti-necroptotic effects of necrostatin-1 and melatonin (Bao et al., 2019). Lysosomal degradation of A20 has been reported to be

**FIGURE 3** | In response to LPS stimulation, A20 is reported to inhibit pyroptosis by the following mechanisms: ① A20 inhibit pyroptosis through inhibiting NF-κB signaling, resulting in the down-regulation of NLRP3 and pro-IL-1β; ② A20 directly interact with the ubiquitylated pro-IL-1β complex, consisting of pro-Caspase-1, pro-Caspase-8, RIPK1 and RIPK3, and then inhibit the formation of RIPK3-dependent K63-Linked polyubiquitin chains of pro-IL-1β, and further repressing the conversion of pro-IL-1β to mature IL-1β; ③ A20 stabilize M1-Linked polyubiquitin chains of RIPK1 by preventing its CYLD-mediated degradation through its ZnF7 domain, then preventing NLRP3 inflammasome activation by inhibiting RIPK1-dependent, RIPK3-MLKL-mediated macrophage necroptosis; ④ A20 may limit necroptosis-induced NLRP3 inflammasome activation by suppressing the potassium efflux.

**FIGURE 4** | A20 can regulate autophagy by the following mechanisms: ① A20 remove the K63-Linked polyubiquitin chains of Beclin1 through its OTU domain; ② A20 affect the ubiquitination level of mTOR through its ZnF7 domain; ③ A20 interact with ATG16L1 to regulate autophagy.
related to the necroptosis of endothelial cells in Alzheimer’s disease (Zou et al., 2020). Resveratrol can relieve chlorothalonil-induced necroptosis through up-regulation of A20 in fish kidney cells (Li et al., 2020). Taken together, these studies can be concluded that A20 can ameliorating different kinds of disease, not only by suppressing apoptosis, but also necroptosis. The underlying mechanism by which A20 regulating necroptosis may be related to that A20 can inactive RIPK3 by regulating the K63-Linked polyubiquitination modification of RIPK3, then suppressing necroptosis (Zhou et al., 2021). Onizawa et al. also found that A20 deficient T cells and fibroblasts are susceptible to caspase independent and RIPK3 dependent necroptosis, which is related to that A20 can restrict the K63-Linked polyubiquitination modification of RIPK3 through its deubiquitinating motif, preventing the formation of RIPK1-RIPK3 complexes and inhibiting necroptosis (Onizawa et al., 2015). Moreover, another study demonstrated that in the LPS/TLR signaling, A20 can prevent NLRP3 inflammasome activation by inhibiting RIPK1 kinase-dependent, RIPK3 - MLKL-mediated macrophage necroptosis, through its ZnF7 domain, and this process may be closely related to that A20 can stabilize M1-Linked ubiquition chains of RIPK1 by preventing its degradation by CYLD, which is also relevant for its function in repressing pyroptosis (Polykratis et al., 2019). Besides, it has been reported that A20 can inhibit necroptosis by affecting the activity of RIPK1 (Iorga et al., 2021; Wang Y et al., 2021) (Figures 2, 3). Taken together, there may be overlapping function of A20 in regulating necroptosis and apoptosis, as well as pyroptosis (see in the next section), which deserve being paid more attention to. The overlapping function of A20 in different pathways may have important implications for the treatment of chronic inflammatory diseases in the future.

A20 and Pyroptosis

Pyroptosis is another form of PCD that is dependent on NLRP3 inflammasomes. The process is accompanied by the release of numerous inflammatory cytokines and is therefore also known as “inflammatory necrosis” (Lamkanfi and Dixit, 2014). NLRP3 expression is upregulated by the upstream transcription factor, NF-κB. Subsequently, ASC and pro-caspase-1 proteins are recruited and assembled to form NLRP3 inflammasomes. This is followed by the activation of caspase-1, which in turn shears gaskermin D (GSDMD) to active GSDMD-N; the latter can induce pore formation and cause leakage of cellular contents such as IL-1β and IL-18 as well as the massive efflux of potassium ions, leading to cell swelling and lysis (Cao et al., 2021). In cerebral hemorrhage, the upregulation of A20 expression can inhibit NLRP3-mediated programmed cell death (Lu et al., 2019). In diseases such as osteoarthritis (Vande et al., 2014), endotoxic shock (Xue et al., 2019), diabetic nephropathy (Ding et al., 2021), Parkinson’s disease (Mouton-Liger et al., 2018), and neuroinflammation (Voet et al., 2018). A20 can inhibit pyroptosis by suppressing the activation of NLRP3 inflammasomes. Studies have found that A20 can inhibit pyroptosis through inhibiting NF-κB signaling, resulting in the down-regulation of NLRP3 and pro-IL-1β (Cornut et al., 2020; Lopez-Castejon, 2020). Nevertheless, some studies showed that blocking NF-κB cannot reverse the arthritic phenotype in A20-deficient mouse, suggesting that there might be another mechanism that concerning A20 regulation pyroptosis. The studies proposed that after LPS engagement, A20 can directly interact with the ubiquitlated pro-IL-1β complex, consisting of pro-caspase-1, pro-caspase-8, RIPK1 and RIPK3, which formed prior to assembly of the NLRP3 inflammasome, and then inhibit the formation of RIPK3-dependent K63-Linked ubiquitination chains of pro-IL-1β, and further repressing the conversion of pro-IL-1β to mature IL-1β (Vande et al., 2014; Duong et al., 2015). Moreover, another study demonstrated that A20 can prevent NLRP3 inflammasome activation by inhibiting RIPK1 kinase-dependent, RIPK3-MLKL-mediated macrophage necroptosis through its ZnF7 domain, and this process may be closely related to that A20 can stabilize M1-Linked ubiquition chains of RIPK1 by preventing its CYLD-mediated degradation by CYLD (Polykratis et al., 2019). Martens et al. also found that A20/ZnF7/ZnF7 BMDMs showed significantly enhanced NLRP3 inflammasome mediated caspase-1 activation, pyroptosis and IL-1β and IL-18, they illustrated that the ZnF7 domain of A20 is very for preserving TNFR1 complex integrity, and for preventing cell death, inflammasome activation and inflammation. which reinforce the idea that A20 can utilize its ZnF7 domain to restrict the activation of NLRP3 inflammasome in macrophage (Vande et al., 2014; Martens et al., 2020). However, Razani et al. reported the exact opposite result. They found that despite increased LPS induced responses, A20/ZnF7/ZnF7 macrophages failed to secrete IL-1β after stimulation with LPS alone, furthermore arthritis in A20/ZnF7/ZnF7 mice is not abrogated by NLRP3 inflammasome deficiency (Razani et al., 2020). We think that these contradictory results may be related to the following reasons: First, Razani et al. only utilized LPS stimulated the A20/ZnF7/ZnF7 macrophages, but Martens et al. utilized LPS plus ATP, since extracellular ATP is indispensable in activating the NLRP3 inflammasome in the second signal, perhaps the use of ATP or not may make a difference, and Duong et al. also reported that LPS alone cannot stimulate A20/ZnF7/BMDM cells secrete additional IL-1β, in contrast, addition of ATP to these cells induced robust IL-1β secretion (Duong et al., 2015); Second, the ZnF4 domain may also play a synergistic role in the regulation of NLRP3 inflammasome activation, because A20/ZnF7/ZnF7 macrophages displayed spontaneous NLRP3 inflammasome activity. But these are just our assumptions and have not been confirmed by more detailed experiments. Taken together, the link between ZnF7 domain of A20 and NLRP3 is controversial, more studies will be need to clarify the function of ZnF7, especially the coordinated function of ZnF7 and ZnF4. Studies also showed that RIPK3-MLKL necrotic signaling can activate the NLRP3 inflammasome in a cell-intrinsic manner. They also demonstrated that oligomerization and association of MLKL with cellular membranes, and a reduction in intracellular potassium concentration can be linked to MLKL-induced necroptosis with NLRP3 activation (Munoz-Planillo et al., 2013; Conos et al., 2017), so we think that A20 may limits necroptosis-induced NLRP3 inflammasome activation by suppressing the potassium efflux, but more research will be required to fully confirm this hypothesis. In summary, A20 can
regulate pyroptosis not only by inhibiting NF-κB-dependent NLRP3 and pro-IL-1β upregulation, but also by repressing the formation of RIPK3-dependent K63-Linked polyubiquitin chains of pro-IL-1β, and necroptosis-inducing NLRP3 inflammasome activation.

A20 and Autophagy

Autophagy is a cathepsin-dependent, and highly conserved process for the degradation of intracellular waste (Dikic and Elazar, 2018). Autophagy is divided into Atg5-Atg12-mediated and Beclin1-mediated pathways. The formation of autophagosomes possessing double-membrane vesicles is the most important mechanism for the occurrence of autophagy. Moreover, Beclin1 expression is positively correlated with autophagy levels. Studies have shown that A20 can inhibit TLR4-induced autophagy through its OTU structural domain by removing the K63-Linked polyubiquitin chain from the lysine residue 117 of Beclin1 (Shi and Kehrl, 2010). Vettes et al. showed that A20 can, through its ZnF7 structural domain, affect the ubiquitination level of mTOR and maintain the balance in the quantity of NK and CD4+ T cells in vivo (Matsuzawa et al., 2015; Vettes et al., 2019). Furthermore, A20 can maintain the stability of the intestinal epithelial barrier by interacting with ATG16L1, a key protein of autophagy (Slowicka et al., 2019). Under hypoxic conditions, A20 inhibits autophagy and thus osteoclastogenesis by affecting the level of TRAF6 ubiquitination (Yan et al., 2020). Moreover, in human ankylosing spondylitis, A20 induces early autophagy by stabilizing mTOR-interacting protein and attenuates the inflammatory responses and autoimmune diseases. In recent years, several studies have confirmed that A20 can not only regulate inflammatory responses, but also play a important role in regulating cell death, like apoptosis, necroptosis, pyroptosis, autophagy. Among other mechanisms, it can affect the NF-κB signaling pathway in both catalytic and non-catalytic pathways, hydrolyze the polyubiquitin chain of caspase proteins, inhibit the expression of NLRP3 inflammasomes, and affect the ubiquitination levels of pro-IL-1β, mTOR, Beclin-1, and TRAF6 in both catalytic and noncatalytic pathways. However, it is worth noting that A20 may have different modes of action in different cell types. Therefore, more studies are needed to confirm the specificity of A20 sites of action, which could provide a theoretical basis for presenting A20 as a new target for disease therapy in the future.

CONCLUSION AND PERSPECTIVES

A20 was initially thought to be a major negative regulator of the NF-κB signaling pathway, and studies on A20 focused on its inhibitory effects on inflammatory responses and autoimmune diseases. In recent years, several studies have confirmed that A20 can not only regulate inflammatory responses, but also play a important role in regulating cell death, like apoptosis, necroptosis, pyroptosis, autophagy. Among other mechanisms, it can affect the NF-κB signaling pathway in both catalytic and non-catalytic pathways, hydrolyze the polyubiquitin chain of caspase proteins, inhibit the expression of NLRP3 inflammasomes, and affect the ubiquitination levels of pro-IL-1β, mTOR, Beclin-1, and TRAF6 in both catalytic and noncatalytic pathways. However, it is worth noting that A20 may have different modes of action in different cell types. Therefore, more studies are needed to confirm the specificity of A20 sites of action, which could provide a theoretical basis for presenting A20 as a new target for disease therapy in the future.

AUTHOR CONTRIBUTIONS

WB: collected the literature and wrote the original manuscript; SH and JL: classified literatures and literature research; JS: manuscript final version approval. All authors contributed to the article and approved the submitted version.

FUNDING

This work was subsidized by the National Natural Science Foundation of China (Grant Number 81960250), and the Yunling Industry Technology Leading Talent Training program of Yunnan Province (Grant Number YXL20170054).

REFERENCES

Angolano, C., Kaczmarek, E., Essayagh, S., Daniel, S., Choi, L. Y., Tung, B., et al. (2021). A20/TNFαIP3 Increases ENOS Expression in an ERK5/KLF2-dependent Manner to Support Endothelial Cell Health in the Face of Inflammation. Front. Cardiovasc. Med. 8, 651230. doi:10.3389/fcvm.2021.651230

Bao, Z., Fan, L., Zhao, L., Xu, X., Liu, Y., Chao, H., et al. (2019). Silencing of A20 Aggravates Neuronal Death and Inflammation after Traumatic Brain Injury: A Potential Trigger of Necroptosis. Front. Mol. Neurosci. 12, 222. doi:10.3389/fnmol.2019.00222

Bellail, A. C., Olson, J. J., Yang, X., Chen, Z. J., and Hao, C. (2012). A20 Ubiquitin Ligase-Mediated Polyubiquitination of RIP1 Inhibits Caspase-8 Cleavage and TRAIL-Induced Apoptosis in Glioblastoma. Cancer Discov. 2 (2), 140–155. doi:10.1158/2159-8290.CD-11-0172

Cao, X., Wang, Y., and Gao, L. (2021). CHRFAM7A Overexpression Attenuates Cerebral Ischemia-Reperfusion Injury via Inhibiting Microglia Pyroptosis Mediated by the NLRP3/Caspase-1 Pathway. Inflammation 44 (3), 1023–1034. doi:10.1007/s10753-020-01398-4

Chen, X., Qian, B., Kong, X., Hao, J., Ye, Y., Yang, K., et al. (2019). A20 Protects Neuronal Apoptosis Stimulated by Lipopolysaccharide-Induced Microglial Exosomes. Neurosci. Lett. 712, 134480. doi:10.1016/j.neulet.2019.134480

Chen, Y., Wu, W., Li, X., Guo, Y., Lu, F., Man, M., et al. (2020). A20 Down-Regulation Promotes UVB-Induced Inflammation via Activation of the NF-κB Pathway. J. Dermatol. Sci. 98 (1), 61–64. doi:10.1016/j.jdermsci.2020.02.007

Cohen, P., and Strickson, S. (2017). The Role of Hybrid Ubiquitin Chains in the MyD88 and Other Innate Immune Signalling Pathways. Cell Death Differ. 24 (7), 1153–1159. doi:10.1038/cdd.2017.17

Conos, S. A., Chen, K. W., De Nardo, D., Hara, H., Whitehead, L., Núñez, G., et al. (2017). Active MLKL Triggers the NLRP3 Inflammasome and Cytotoxicity in a Cell-Intrinsic Manner. Proc. Natl. Acad. Sci. U S A. 114 (6), E961–E969. doi:10.1073/pnas.1613301114

Corrunt, M., Bourdouffay, E., and Henry, T. (2020). Transcriptional Regulation of Inflammasomes. Int. J. Mol. Sci. 21 (21), 8087. doi:10.3390/ijms21218087

Dikic, I., and Elazar, Z. (2018). Mechanism and Medical Implications of Mammalian Autophagy. Nat. Rev. Mol. Cell. Biol. 19 (6), 349–364. doi:10.1038/s41580-018-0003-4

Ding, X., Jing, N., Shen, A., Guo, F., Song, Y., Pan, M., et al. (2021). MiR-21-5p in Macrophage-Derived Extracellular Vesicles Affects Podocyte Pyroptosis in Diabetic Nephropathy by Regulating A20. J. Endocrinol. Invest. 44 (6), 1175–1184. doi:10.1007/s40618-020-01401-7

Draber, P., Kupka, S., Reichert, M., Draberova, H., Lafont, E., de Miguel, D., et al. (2015). LUBAC-recruited CYLD and A20 Regulate Gene Activation and Cell Death by Exerting Opposing Effects on Linear Ubiquitin in

Frontiers in Pharmacology | www.frontiersin.org May 2022 | Volume 13 | Article 845262

8
Bai et al. Ubiquitin-Editing Enzyme A20

Jia, F., Deng, F., Xu, P., Li, S., Wang, X., Hu, P., et al. (2021). NOD1 Agonist

Hutti, J. E., Turk, B. E., Asara, J. M., Ma, A., Cantley, L. C., and Abbott, D. W.

Hitotsumatsu, O., Ahmad, R. C., Tavares, R., Wang, M., Philpott, D., Turer, E. E.,

Guo, T., Zhang, Y., Qu, X., Che, X., Li, C., Fan, Y., et al. (2020). miR-200a Enhances

Hinz, M., Arslan, S. Ç., and Scheidereit, C. (2012). It Takes Two to Tango: I

Garcia-Carbonell, R., Wong, J., Kim, J. Y., Close, L. A., Boland, B. S., Wong, T. L.,

Düwel, M., Welteke, V., Oeckinghaus, A., Baens, M., Kloo, B., Ferch, U., et al.

Düwel, M., Welteke, V., Oeckinghaus, A., Baens, M., Kloo, B., Ferch, U., et al.

Duong, B. H., Onizawa, M., Oses-Prieto, J. A., Advincula, R., Burlingame, A.,

Dong, H., Lamkanfi, M., and Dixit, V. M. (2014). A20 Restricts Ubiquitination of Pro-interleukin-1β Protein Complexes and Suppresses NLRP3 Inflammasome Activity. *Immunity* 42 (1), 55–67. doi:10.1016/j.immuni.2014.12.031

Düwel, M., Welteke, V., Oeckinghaus, A., Baens, M., Kloo, B., Ferch, U., et al. (2009). A20 Negatively Regulates T Cell Receptor Signaling to NF-kappaB by Cleaving Malt1 Ubiquitin Chains. *J. Immunol.* 182 (12), 7718–7728. doi:10.4049/jimmunol.0803313

Düwel, M., Welteke, V., Oeckinghaus, A., Baens, M., Kloo, B., Ferch, U., et al. (2009). A20 Negatively Regulates T Cell Receptor Signaling to NF-kappaB by Cleaving Malt1 Ubiquitin Chains. *J. Immunol.* 182 (12), 7718–7728. doi:10.4049/jimmunol.0803313


doi:10.1101/9202351

Fu, B., Lin, X., Tan, S., Zhang, R., Xue, W., Zhang, H., et al. (2021). MiR-342 Controls *Mycobacterium tuberculosis* Susceptibility by Modulating Inflammation and Cell Death. *EMBO Rep.* 22 (9), e52252. doi:10.2233/emb.202052252

Gao, P., Ma, X., Yuan, M., Yi, Y., Liu, G., Wen, M., et al. (2021). E3 Ligase Nedd4L Promotes Antiviral Innate Immunity by Catalyzing K29-Linked Cysteine Ubiquitination of TRAF3. *Nat. Commun.* 12 (1), 1194. doi:10.1038/s41467-021-21456-1

Garcia-Carbonell, R., Wong, J., Kim, J. Y., Close, L. A., Boland, B. S., Wong, T. L., et al. (2018). Elevated A20 Promotes TNF-Dependent Intestinal Epithelial Cell Death. *Proc. Natl. Acad. Sci. U S A.* 115 (39), E9192–E9200. doi:10.1073/pnas.180584115

Goldstein, G., Scheid, M., Hammerling, U., Schliesing, D. H., Niial, H. D., and Boyse, E. A. (1975). Isolation of a Polypeptide that Has Lymphocyte-Differentiating Properties and Is Probably Represented Universally in Living Cells. *Proc. Natl. Acad. Sci. U S A.* 72 (1), 11–15. doi:10.1073/pnas.72.1.11

Guo, T., Zhang, Y., Qu, X., Che, X., Li, C., Fan, Y., et al. (2018). miR-200a Enhances TRAIL-Induced Apoptosis in Gastric Cancer Cells by Targeting A20. *Cell Biol. Int.* 42 (5), 506–514. doi:10.1002/cbin.10924

Haakonsen, D. L., and Rape, M. (2019). Branching Out: Improved Signaling by Deubiquitinating Enzyme A20. *Cold Spring Harb. Perspect. Biol.* 12 (1). doi:10.1101/s41590-020-0621-9

Hansen, B. A., and Ma, A. (2019). A20: A Multifunctional Tool for Regulating Inflammation, and Cell-Protective Activities. *Cold Spring Harb. Perspect. Biol.* 12 (1). doi:10.1101/cshperspect.a036418

Hansen, B. A., and Ma, A. (2019). A20: A Multifunctional Tool for Regulating Inflammation, and Cell-Protective Activities. *Cold Spring Harb. Perspect. Biol.* 12 (1). doi:10.1101/cshperspect.a036418
Matsuzawa, Y., Oshima, S., Takahara, M., Maeyashi, C., Nemoto, Y., Kobayashi, M., et al. (2015). TNFAIP3 Promotes Survival of CD4 T Cells by Restricting MTOF and Promoting Autophagy. *Autophagy* 11 (7), 1052–1062. doi:10.1080/15548627.2015.1055439

Moebeian, A. N., Ramphal, N. S., Karram, K. D., Liberto, G., Novkovic, T., Klein, M., et al. (2020). Microglial A20 Protects the Brain from CD8 T-Cell-Mediated Immunopathology. *Cel. Rep.* 30 (5), 1585–e6. doi:10.1016/j.celrep.2019.12.097

Momtazi, G., Lambrecht, B. N., Naranjo, J. R., and Schock, B. C. (2019). Regulators of A20 (TNFAIP3): New Drug-Targetable Targets in Inflammation. *Am. J. Physiol. Lung Cel. Mol. Physiol.* 316 (3), L456–L469. doi:10.1152/ajplung.00335.2018

Mouton-Liger, F., Rosazza, T., Sepulveda-Diaz, J., Ieang, A., Hassoun, S. M., Claire, E., et al. (2018). Parkin Deficiency Modulates NLRP3 Inflammasome Activation by Attenuating an A20-Dependent Negative Feedback Loop. *Glia* 66 (8), 1736–1751. doi:10.1002/glia.23337

Muñoz-Planillo, R., Kuffa, P., Martínez-Colón, G., Smith, B. L., Rajendiran, T. M., Mouton-Liger, F., Rosazza, T., Sepulveda-Diaz, J., Ieang, A., Hassoun, S. M., Claire, E., et al. (2018). Parkin Deficiency Modulates NLRP3 Inflammasome Activation by Attenuating an A20-Dependent Negative Feedback Loop. *Glia* 66 (8), 1736–1751. doi:10.1002/glia.23337

Onizawa, M., Oshima, S., Schulze-Topphoff, U., Oses-Prieto, J. A., Lu, T., Tavares, R. M., Turer, E. E., Liu, C. L., Advincula, R., Scapini, P., Rhee, L., et al. (2015). The Ubiquitin Modifying Enzyme A20 Restricts B Cell Survival and Prevents Autoimmunity. *Immunity* 33 (2), 181–191. doi:10.1016/j.immuni.2010.07.017

Taylor, R. C., Cullen, S. P., and Martin, S. J. (2008). Apoptotic Controlled Demolition at the Cellular Level. *Nat. Rev. Mol. Cel. Biol.* 9 (3), 231–241. doi:10.1038/nrm2312

Tracz, M., and Bialek, W. (2021). Beyond K48 and K63: Non-Canonical Protein Ubiquitination. *Cell Mol. Biol. Lett.* 26 (1), 1. doi:10.1016/s11658-020-00245-6

Vande Walle, L., Van Opdenbosch, N., Jacques, P., Fossou, A., Verheugen, E., Vogel, P., et al. (2014). Negative Regulation of the NLPR3 Inflammasome by A20 Protects Against Arthritis. *Nature* 512 (7512), 69–73. doi:10.1038/nature13322

Vetters, J., van Helden, M. J., Wahlen, S., Tavernier, S. J., Martens, A., Fayazpour, F., et al. (2019). The Ubiquitin-Editing Enzyme A20 Controls NK Cell Homeostasis Through Regulation of mTOR Activity and TNF. *J. Exp. Med.* 216 (9), 2010–2023. doi:10.1084/jem.20182164

Voet, S., Mc Guire, C., Hagemeyer, N., Martens, A., Schroeder, A., Wieghofer, P., et al. (2018). A20 Critically Controls Microglia Activation and Inhibits Inflammation-Dependent Neuroinflammation. *Nat. Commun.* 9 (1), 2036. doi:10.1038/s41467-018-0376-5

Wang, H. H., Qi, W., Zou, C., Xie, Z., Zhang, M., Naito, M. G., et al. (2021). Neki-Mediated Retromer Trafficking Promotes Blood-Brain Barrier Integrity by Regulating Glucose Metabolism and RIPK1 Activation. *Nat. Commun.* 12 (1), 4826. doi:10.1038/s41467-021-25157-7

Wang J., Zhong, W., Su, H., Xu, J., Yang, D., Liu, X., et al. (2021). Histone Methyltransferase Dot1L Contributes to RIPK1 Kinase-Dependent Apoptosis in Cerebral Ischemia/Reperfusion. *Jalu* 10 (23), 0022791. doi:10.1161/JAHA.121.022791

Wang, Y., Wen, H., Fu, J., Cai, L., Li, P. L., Zhao, C. L., et al. (2020). Hepatocyte TNF Receptor-Associated Factor 6 Aggravates Hepatic Inflammation and Fibrosis by Promoting Lyseine 6-Linked Polysubiquitination of Apoptosis Signal-Regulating Kinase 1. *Hepatology* 71 (1), 93–111. doi:10.1002/hep.30822

Wang Y., Yang, Z., Wang, Q., Ren, Y., Wang, Q., and Li, Z. (2021). Bavachinin Exerted Anti-Inflammatory Effects by Regulation of A20 Ubiquitin-Editing Complex. *Int. Immunopharmacol.* 100, 108085. doi:10.1016/j.intimp.2021.108085

Wertz, I. E., Newton, K., Seshasayee, D., Kusam, S., Lan, C., Zhang, J., et al. (2015). Phosphorylation and Linear Ubiquitin Direct A20 Inhibition of Inflammation. *Nature* 528 (7582), 370–375. doi:10.1038/nature16165

Wertz, I. E., O’Rourke, K. M., Zhou, H., Eby, M., Aravind, L., Seshagiri, S., et al. (2004). De-Ubiquitination and Ubiquitin Ligase Domains of A20 Downregulate NF-kappaB Signalling. *Nature* 430 (7000), 694–699. doi:10.1038/nature02794

Wilson, N. S., Dixit, V., and Ashkenazi, A. (2009). Death Receptor Signal Transducers: Nodes of Coordination in Immune Signaling Networks. *Nat. Immunol.* 10 (4), 348–355. doi:10.1038/ni.1714

Xue, Z., Xi, Q., Liu, H., Guo, X., Zhang, J., Zhang, Z., et al. (2019). miR-21 Promotes NLPR3 Inflammasome Activation to Mediate Pyroptosis and Endotoxic Shock. *Cel. Dis. Ther.* 10 (6), 461. doi:10.1038/s41419-019-1713-z

Yan, K., Wu, C., Ye, Y., Li, L., Wang, X., He, W., et al. (2020). A20 Inhibits Osteoclastogenesis via TRAF6-Dependent Autophagy in Human Periodontal Ligament Cells Under Hypoxia. *Cell Prolif.* 53 (3), e12778. doi:10.1111/cpr.12778

Yu, X., Li, W., Deng, Q., Liu, H., Wang, X., Hu, H., et al. (2021). MYY88 L265P Elicits Mutation-Specific Ubiquitination to Drive NF-kB Activation and Lymphomagenesis. *Blood* 137 (12), 1615–1627. doi:10.1182/blood.2020004918

Yuan, W., Chen, Y., Zhou, Y., Bao, K., Yu, X., Xu, Y., et al. (2021). Formononetin Attenuates Atopic Dermatitis by Upregulating A20 Expression via Activation of G Protein-Coupled Estrogen Receptor. *J. Ethnopharmacol.* 266, 113397. doi:10.1016/j.jep.2020.113397

Zhai, Y., Lin, P., Feng, Z., Lu, H., Han, Q., Chen, J., et al. (2018). TNFAIP3-DEPTOR Complex Regulates Inflammasome Secretion Through Autophagy in Anklyosing Spondylitis Monocytes. *Autophagy* 14 (9), 1629–1643. doi:10.1080/15548627.2018.1458804

Zhang, H., Zhou, X., Mcquade, T., Li, J., Chan, F. K., and Zhang, J. (2011). Functional Complementation Between FADD and RIP1 in Embryos and Lymphocytes. *Nature* 471 (7388), 373–376. doi:10.1038/nature09878
Zheng, Z., Qu, J. Q., Yi, H. M., Ye, X., Huang, W., Xiao, T., et al. (2017). MiR-125b Regulates Proliferation and Apoptosis of Nasopharyngeal Carcinoma by Targeting A20/NF-κB Signaling Pathway. *Cell Death Dis.* 8 (6), e2855. doi:10.1038/cddis.2017.211

Zhou, J., Wu, L. Y., Chen, L., Guo, Y. J., Sun, Y., Li, T., et al. (2019). Herbs-Partitioned Moxibustion Alleviates Aberrant Intestinal Epithelial Cell Apoptosis by Upregulating A20 Expression in a Mouse Model of Crohn’s Disease. *World J. Gastroenterol.* 25 (17), 2071–2085. doi:10.3748/wjg.v25.i17.2071

Zhou, M., He, J., Shi, Y., Liu, X., Luo, S., Cheng, C., et al. (2021). ABIN3 Negatively Regulates Necroptosis-Induced Intestinal Inflammation Through Recruiting A20 and Restricting the Ubiquitination of RIPK3 in Inflammatory Bowel Disease. *J. Crohns Colitis.* 15 (1), 99–114. doi:10.1093/ecco-jcc/jja131

Zou, C., Miflin, L., Hu, Z., Zhang, T., Shan, B., Wang, H., et al. (2020). Reduction of mNAT1/hNAT2 Contributes to Cerebral Endothelial Necroptosis and Aβ Accumulation in Alzheimer’s Disease. *Cell Rep.* 33 (10), 108447. doi:10.1016/j.celrep.2020.108447

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Bai, Huo, Li and Shao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.